References
- Sargent W. The effect of anxiety states and atypical depressions by the MAOI drugs. J. Neuropsychiatry 1962; 3: 96–103
- Jenike M. A., Surman O. S., Cassem N. H. Monoamine oxidase inhibitors in obsessive -compulsive disorder. J. Clin. Psychiatry 1983; 44: 131–132
- Akil H. J., Liebeskind J. C. Monoaminergic mechanisms of stimulation-produced analgesics. Brain Res. 1975; 94: 279–296
- Anthony M., Lance J. W. Monoamine oxidase inhibition in the treatment of migraine. Arch. Neurol. 1969; 21: 263–268
- Liebowitz M. R., Quitkin F., Stewart J. W. Phenelzine and Imipramine in atypical depression. Psychopharamcol. Bull. 1981; 17: 159–161
- Walsh B. T., Stewart J. W., Wright L. Treatment of bulimia with monoamine oxidase inhibitors. Am. J. Psychiatry 1982; 139: 1629
- Goodman W. K., Charney D. S. Therapeutic applications of mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. J. Clin. Psychiatry 1985; 4: 6–22
- Council on Drugs. Paradoxical hypertension from tranylcypromine sulfate. J. Am. Med. Assoc. 1963; 186: 854
- Swanson D. W., Weddige R. L., Morse R. M. Abuse of prescription drugs. Mayo Clin. Proc. 1973; 48: 359–367
- Pitt B. Withdrawal symptoms after stopping phenelzine. Br. Med. J. 1974; 2: 332–333
- Hynes M. D., Lochner M. A., Bernis K. G. Thioxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors. Life Sci. 1985; 36: 2317–2323
- Petraglia F., Facchinetti F., Martignonni E. Serotinergic agonists increase plasma levels of B -endorphin and B-lipoprotein in humans. J. Clin. Endocrinol. Metab. 1984; 59: 1138–1142
- Jespersen S., Scheel-Kruger J. Evidence for a difference in mechanism of action between fenfluramine- and amphetamine-induced anorexia. J. Pharm. Pharmacol. 1973; 25: 49–54
- Westermeyer J. A Clinical Guide to Alcohol and Drug Problems. Praeger, Philadelphia 1986